Drug Aproval and Phase of Clinical Research
                     Drug Approval and 
Phases of Clinical 
Research
INTRODUCTION
You are in the life sciences, so you are already aware that developing a 
drug to market is a lengthy process. What is less evident is that every 
stage of clinical research leads to the ultimate approval decision. Knowing 
the various drug development phases in the clinic can make you realize 
the location of risks, the location where expenses increase, and the 
location where intelligent planning will save you years.
This paper takes you through the entire journey, starting with early human 
research to regulatory acceptance, with a good overview of therapeutic 
areas of clinical trials, the contribution of a clinical research organisation, 
and how orphan drug development takes a slightly different route.
Between Discovery and First-in-
Human Studies
Researchers do pre-clinical testing of a compound in laboratories and in 
animal models before the commencement of clinical trials. This preclinical 
has primary safety and biological activity checks. When findings are in 
favour of human testing the sponsor forwards the information to the 
authorities and requests authorization to commence clinical trials.
The green light is the start of the actual work. This is the point at which 
clinical drug development stages begin to influence the drug future.
Phase 0 and Phase I: Let the 
safety first
Phase 0 studies are present in some of the programs. These are tiny, preclinical tests 
that determine the behavior of a drug in the body. All drugs do not pass through this 
stage.
Phase I is more common. These trials include a limited number of healthy volunteers or 
patients, with regard to the drug. The objective is straightforward: inform about the 
safety and dosage knowledge.
The absorption, distribution, metabolism and excretions of the drug are monitored by the 
researchers. They also observe side effects. At this point, the question of whether or not 
the drug works well does not matter. It has to do with ensuring that it does not cause 
harm when it is taken in planned doses.
These trials are usually administered by a clinical research organisation. The CROs are 
involved in site selection, monitoring and data collection and they assist the sponsors to 
work at a faster pace and still retain control over quality.
Phase II: Does the drug work?
The phase II trials provide an answer to the important question: does the drug 
provide any benefit in patients?
More participants are recruited and specific therapy areas (in clinical trials) are 
targeted in these studies including oncology, cardiology, neurology or rare 
diseases. Scientists experiment with various doses and safety is followed up.
This stage determines the destiny of the program. Poor performance tends to halt 
progress in this case. Powerful data is used to support bigger and costly studies.
Phase II may have a different appearance in orphan drugs development. Due to 
the low number of patients, trials tend to employ less participants and other study 
designs. Regulators realize that these limits are flexible and provided that the 
science is sound.
Phase III: Proof at scale
The most costly and the longest phase is phase III. Such trials include 
hundreds or thousands of patients in a variety of places. This is aimed at 
establishing effectiveness, checking side effects, and ensuring the 
comparison of the drug with the already existing treatment.
This stage is the foundation of the approval application because of the 
data it provides. The regulators scrutinize it. Any loopholes, discrepancies, 
or warning signs are of concern.
In this case, a clinical research organisation is at the centre stage. The big 
trials demand great coordination, good data systems and adherence to the 
rules. This stage is very critical and improper execution will make approval 
take years.
Regulatory Inspection and 
Certification
After the Phase III is completed, the sponsor will submit a complete 
application to the regulators. This is a Biologics License Application or a 
New Drug Application in the US. It passes through the EMA and national 
agencies in Europe.
Regulators consider clinical information, production information and 
labeling. They conclude on the extent of benefits and risks against the 
target group of patients.
Clinical research does not necessarily come to an end when it is approved. 
A large number of drugs go through Phase IV after the launch.
Phase IV: Real-world evidence
Post-approval trials occur during phase IV. They are followed on long-term 
safety and effectiveness in real-world situations. In some cases, regulators 
mandate such studies in order to grant approval.
In clinical trials of drugs in sensitive therapeutic areas, in which marketers 
have a strong interest, post-marketing data is particularly crucial, e.g. in 
pediatrics or in rare diseases. It aids in narrowing the dose, broadening 
indications, and risk management with time.
Extra Steps in the Development 
of Orphan Drugs
The focus of developing orphan drugs is on rare diseases. The number of 
patients is low, and there is a high level of unmet medical needs. Some of 
the incentives that are provided by regulators include market exclusivity 
and fee cuts.
Still, clinical drug development stages are applicable, although trial 
designs tend to change. It has single-arm trials, surrogate endpoints, and 
accelerated approvals. Data tracking and historical controls are essential.
Trial intelligence can be accessed to make better decisions in this space. 
Knowledge of the things that have been proven to be effective assists 
sponsors in eliminating errors and setting achievable schedules.
Why Structured Data Matters
In all stages, information quality is a success factor. Sponsors must have 
visibility of trial design, endpoints, focus of therapy and regulatory 
outcome. It is on this platform that such sites as Clival Database 
contribute value.
The Clival Database assists teams in maintaining the activity of a clinical 
research in terms of therapeutic area, phase of the trial and location. As 
you are aware of the way other similar programs went before, you plan 
trials more successfully and minimize unnecessary delays.
Final Thoughts
The way to drug approval is clear-cut although no two programs have 
similar appearance. One stage is based on the previous one, and the poor 
performance at the initial stage makes the future troublesome.
When you know the phases of clinical drug development, collaborate with 
a well-competent clinical research organisation and prepare strategies 
towards areas such as orphan drug development, your success will be 
enhanced.
The field of clinical research is complicated. However, with the appropriate 
data and planning, you will be able to go through it with fewer surprises 
and confidence.
WEBSITE : WWW.CLIVAL.
COM
 
• WWW.LIFESCIENCEINTELLIPEDIA.COM 
• WWW.CHEMXPERT.COM
LOCATION:- C-89, SECTOR-65 NOIDA-U.P. 201301 
(INDIA)
E-MAIL:- [email protected] | 
[email protected] 
PHONE:- +91-120-6631301-335
MOB NO:- +91-9990237670
THANK YOU!